Compare Hormel Foods Corp (HRL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs BIO-TECHNE Corp — how do they compare? Hormel Foods Corp trades at $19.46 (market cap $10.76B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Hormel Foods Corp and BIO-TECHNE Corp are close in size by market cap, and Hormel Foods Corp pays the higher dividend (5.98%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and BIO-TECHNE Corp for 63 Days on average.
| HRL | TECH | |
|---|---|---|
Market Cap | $10.76B | $11.37B |
Volume | 6,064,955 | 3,153,511 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $72.61 |
52-Week Low | $19.42 | $43.31 |
Typical Hold Time | 99 Days | 63 Days |
Enterprise Value | $12.75B | $11.40B |
Dividend Yield | 5.98% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.42, down 2.31% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 31.53 and net margin of 2.82%, while recent earnings beat expectations. The company maintains a 60-year dividend streak but faces margin pressure. Recent $1.06B Brakebush acquisition aims to expand foodservice chicken business, representing significant strategic investment.
Outlook remains cautious with analyst consensus at Hold (57%) and $24.25 price target suggesting 25% upside. Key risks include shrinking dividend raises, margin compression, and integration challenges from recent acquisition. The dividend yield of approximately 3% provides income support, but growth concerns persist amid inflationary pressures.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
